The American drugstore is in the middle of its biggest reinvention in a generation. After a decade of aggressive expansion, the industry’s two biggest chains are now shrinking, while new entrants from Amazon to Mark Cuban’s Cost Plus Drugs are rewriting what a pharmacy even is. The next twelve months will make clear which model survives.
Where the Industry Stands Now
CVS and Walgreens, which together operate the largest pharmacy footprint in the country, have spent the past two years in full retreat. CVS announced plans to close around 900 stores through 2026, while Walgreens has signaled that roughly a quarter of its roughly 8,500 U.S. locations are unprofitable and candidates for closure. Rite Aid, after a second bankruptcy filing, has effectively ceased to exist as a national chain. What was once a three-horse race has narrowed considerably.
The reasons are not mysterious. Reimbursement pressure from pharmacy benefit managers has squeezed prescription margins to the bone. Front-of-store sales, the profitable snacks-and-sundries business that historically subsidized the pharmacy counter, have been hollowed out by Amazon, Walmart, and dollar stores. Labor costs are up, theft losses are up, and foot traffic is down. The old model, where a prescription pickup also meant a tube of toothpaste and a bag of chips, no longer reliably clears the rent.
Amazon Pharmacy, meanwhile, has quietly become one of the fastest-growing parts of Amazon’s business. Same-day prescription delivery is now available in a growing list of U.S. metros, and the RxPass program offers flat-rate generics to Prime members. Independent pharmacies, long left for dead, have actually gained share in some rural markets as chains retreat. And Cost Plus Drugs continues to expose just how much middleman markup exists in the prescription supply chain.
The GLP-1 Factor
No trend has reshaped pharmacy economics faster than the GLP-1 category, the class of drugs that includes Ozempic, Wegovy, Mounjaro, and Zepbound. These medications are now among the top-selling drugs in the United States, and they are reshaping retail in three ways at once. They drive enormous prescription volume, they come with complex insurance and prior-authorization workflows that favor larger operators, and they have spawned a parallel ecosystem of telehealth sellers, compounding pharmacies, and direct-to-consumer brands.
What to Expect in 2026 and 2027
The next year is likely to be defined by five overlapping shifts.
More Closures, More Consolidation
Expect another wave of store closures from both CVS and Walgreens, concentrated in urban cores and overlapping suburban markets. Walgreens, now taken private in a deal with Sycamore Partners, is expected to move faster on restructuring than it could as a public company. Consolidation of independent pharmacies into regional groups is also likely, as owners seek scale to negotiate with PBMs.
AI Moves Into the Script Workflow
Pharmacies are expected to lean heavily on AI for the unglamorous work behind the counter: insurance verification, prior authorization, adherence outreach, and inventory forecasting. Several large chains have already announced pilots using large language models to draft appeals to insurers and to triage patient calls. The goal is less about replacing pharmacists than about freeing them from paperwork so a smaller workforce can handle the same volume.
Automation at the Counter
Robotic dispensing systems, already common in mail-order facilities, are migrating into retail stores. Central fill hubs, where high-volume prescriptions are filled in regional warehouses and shipped to local stores for pickup, are likely to become the default for the biggest chains. That is quietly a massive change in what a drugstore is, since it means the pharmacist in your neighborhood may no longer be counting your pills.
Delivery Becomes the Default
Amazon’s same-day prescription push will almost certainly force competitors to match. Walmart, Kroger, and the surviving national chains are expected to expand two-hour and same-day delivery aggressively in 2026. Walking into a store to pick up a prescription is likely to feel, within a few years, the way going to a Blockbuster felt by 2010: still possible, increasingly optional.
The Clinic-Pharmacy Blur
CVS’s MinuteClinic and Walgreens’s VillageMD partnership represent bets that the surviving stores will be partly clinics. Expect more vaccinations, more basic primary-care visits, and more chronic-disease management happening inside what used to be purely a pharmacy. Insurers are actively pushing this, because a $40 retail clinic visit is cheaper than a $200 urgent-care visit.
What It Means for Consumers
For the average shopper, the practical effects will arrive gradually but noticeably. Your neighborhood pharmacy may close, forcing a transfer. Wait times at the surviving locations are likely to get worse before they get better, because staffing reductions are outpacing volume reductions. Delivery will become genuinely convenient for routine refills, but anything involving a controlled substance or a tricky insurance issue will still require a human conversation, often a long one.
Prices are the wild card. For generics, the trend is clearly downward, thanks to Cost Plus Drugs and Amazon. For branded drugs, especially GLP-1s, the opposite pressure applies, as demand continues to outstrip manageable supply and insurers tighten coverage.
Specific Predictions for the Next Twelve Months
- A major national chain is likely to announce a store count below 6,000 U.S. locations by late 2026.
- Amazon Pharmacy is expected to cross into profitability on a segment basis.
- At least one large insurer is likely to announce a preferred-pharmacy deal that effectively steers members away from CVS or Walgreens.
- Compounded GLP-1s will face tighter FDA enforcement, reshaping the telehealth weight-loss market.
- Expect the first serious acquisitions of regional independent-pharmacy groups by private equity.
What Savvy Shoppers Should Do Now
A few small moves can insulate you from the disruption. Move recurring generic prescriptions to whichever delivery option is cheapest for your specific drugs. For most people, that means comparing Amazon Pharmacy, Cost Plus Drugs, and your current pharmacy’s cash price, because insurance is not always the best deal anymore. Keep a backup pharmacy on file, since closure announcements often come with little warning. If you rely on a specialty medication or a controlled substance, build a relationship with an independent pharmacy now; they tend to be more flexible on partial fills and manual workarounds. And if you use a GLP-1, get your prior authorizations renewed early, because administrative bottlenecks are the single most common reason people lose access.
The Bottom Line
The retail pharmacy is not dying, but the version most Americans grew up with is. Expect fewer stores, more automation, faster delivery, and a much sharper split between commodity prescriptions handled by machines and complex care handled by a shrinking number of human pharmacists.